OBJECTIVE: Estimation of the glomerular filtration rate (GFR) is essential when evaluating patients with kidney disease and treating patients with drugs eliminated from the circulation by the kidneys. Cystatin C has been shown in several studies to be superior to creatinine in the estimation of GFR. At our hospitals, there is an increasing demand for cystatin C and at present we perform approximately 1500 cystatin C analyses a month. We thus need the assay available 24 h/day and to have it on our routine chemistry instrument to minimize handling time per test and time to reported test results. MATERIAL AND METHODS: We have evaluated a new cystatin C immunoassay from Gentian (Gentian, Moss, Norway) on Architect ci8200 (Abbott Laboratories, Abbott Park, Ill., USA). A prerequisite at our hospital is that cystatin C results are reported as a calculated GFR in mL/min/1.73 m(2), so we also made a comparison with iohexol clearance. RESULTS: The Gentian cystatin C assay showed good agreement with the corresponding assay from Dade Behring (Deerfield, Ill., USA) and good inter-laboratory concordance. The assay has very low total imprecision, good linearity and strong correlation with iohexol clearance (R (2) = 0.956). The equation for the correlation curve is: y = 79.901x(-1.4389). CONCLUSIONS: There was low inter-laboratory variation between the three laboratories involved in the cystatin C evaluation, and thus all three laboratories can use the same equation for calculating the estimated GFR.
OBJECTIVE: Estimation of the glomerular filtration rate (GFR) is essential when evaluating patients with kidney disease and treating patients with drugs eliminated from the circulation by the kidneys. Cystatin C has been shown in several studies to be superior to creatinine in the estimation of GFR. At our hospitals, there is an increasing demand for cystatin C and at present we perform approximately 1500 cystatin C analyses a month. We thus need the assay available 24 h/day and to have it on our routine chemistry instrument to minimize handling time per test and time to reported test results. MATERIAL AND METHODS: We have evaluated a new cystatin C immunoassay from Gentian (Gentian, Moss, Norway) on Architect ci8200 (Abbott Laboratories, Abbott Park, Ill., USA). A prerequisite at our hospital is that cystatin C results are reported as a calculated GFR in mL/min/1.73 m(2), so we also made a comparison with iohexol clearance. RESULTS: The Gentian cystatin C assay showed good agreement with the corresponding assay from Dade Behring (Deerfield, Ill., USA) and good inter-laboratory concordance. The assay has very low total imprecision, good linearity and strong correlation with iohexol clearance (R (2) = 0.956). The equation for the correlation curve is: y = 79.901x(-1.4389). CONCLUSIONS: There was low inter-laboratory variation between the three laboratories involved in the cystatin C evaluation, and thus all three laboratories can use the same equation for calculating the estimated GFR.
Authors: R Marsell; M A I Mirza; H Mallmin; M Karlsson; D Mellström; E Orwoll; C Ohlsson; K B Jonsson; O Ljunggren; T E Larsson Journal: Osteoporos Int Date: 2008-10-31 Impact factor: 4.507
Authors: F Iliadis; T Didangelos; A Ntemka; A Makedou; E Moralidis; A Gotzamani-Psarakou; T Kouloukourgiotou; D Grekas Journal: Diabetologia Date: 2011-09-23 Impact factor: 10.122
Authors: Axel C Carlsson; Erik Ingelsson; Johan Sundström; Juan Jesus Carrero; Stefan Gustafsson; Tobias Feldreich; Markus Stenemo; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: Clin J Am Soc Nephrol Date: 2017-07-21 Impact factor: 8.237
Authors: Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447
Authors: Axel C Carlsson; Tobias E Larsson; Johanna Helmersson-Karlqvist; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Axel C Carlsson; Lina Nordquist; Tobias E Larsson; Juan-Jesús Carrero; Anders Larsson; Lars Lind; Johan Ärnlöv Journal: Cardiorenal Med Date: 2015-07-31 Impact factor: 2.041
Authors: Sophie Hawkesworth; Yukiko Wagatsuma; Maria Kippler; Anthony J C Fulford; Shams E Arifeen; Lars-Ake Persson; Sophie E Moore; Marie Vahter Journal: Int J Epidemiol Date: 2012-12-14 Impact factor: 7.196